Biosign Technologies Inc. announced that it has appointed RJL Systems Inc, as a non-exclusive agent for sales of Biosign Pulsewave(R) monitoring system within the United States. In a parallel agreement, Biosign has been appointed by RJL as a non-exclusive agent for their Quantum IV Body Impedance Analysis technology in the United States and Canada, and the parties have agreed to co-market their healthcare IT solutions. The RJL Quantum line of professional body composition analyzers rely on a technology that RJL originated in 1979, called "Bioelectrical Impedance Analysis" (BIA), for precise measurements used to assess and predict lean dry mass, body fat, intracellular and extracellular water, total body water, body mass index, fat free mass, basal metabolic rate, and daily energy expenditure.